Association of treatment at high-volume facilities with survival in patients receiving chemoradiotherapy for nasopharyngeal cancer

Vivek Verma; Pamela K. Allen; Charles B. Simone; Hiram A. Gay; Steven H. Lin

doi:10.1001/jamaoto.2017.1874

Association of treatment at high-volume facilities with survival in patients receiving chemoradiotherapy for nasopharyngeal cancer

Vivek Verma, Pamela K. Allen, Charles B. Simone, Hiram A. Gay, Steven H. Lin

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	86-89
Number of pages	4
Journal	JAMA Otolaryngology - Head and Neck Surgery
Volume	144
Issue number	1
DOIs	https://doi.org/10.1001/jamaoto.2017.1874
State	Published - Jan 2018

Access to Document

10.1001/jamaoto.2017.1874

Cite this

@article{ed9732a897c145e9a1b87cbee288546d,

title = "Association of treatment at high-volume facilities with survival in patients receiving chemoradiotherapy for nasopharyngeal cancer",

author = "Vivek Verma and Allen, {Pamela K.} and Simone, {Charles B.} and Gay, {Hiram A.} and Lin, {Steven H.}",

note = "Funding Information: Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Lin has research funding from Elekta, STCube Pharmaceuticals, Peregrine, Bayer, and Roche/Genentech, has served as a consultant for AstraZeneca, and received honorarium from US Oncology and ProCure. All other authors declare no conflicts of interest.",

year = "2018",

month = jan,

doi = "10.1001/jamaoto.2017.1874",

language = "English",

volume = "144",

pages = "86--89",

journal = "JAMA Otolaryngology - Head and Neck Surgery",

issn = "2168-6181",

number = "1",

}

TY - JOUR

T1 - Association of treatment at high-volume facilities with survival in patients receiving chemoradiotherapy for nasopharyngeal cancer

AU - Verma, Vivek

AU - Allen, Pamela K.

AU - Simone, Charles B.

AU - Gay, Hiram A.

AU - Lin, Steven H.

N1 - Funding Information: Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Lin has research funding from Elekta, STCube Pharmaceuticals, Peregrine, Bayer, and Roche/Genentech, has served as a consultant for AstraZeneca, and received honorarium from US Oncology and ProCure. All other authors declare no conflicts of interest.

PY - 2018/1

Y1 - 2018/1

UR - http://www.scopus.com/inward/record.url?scp=85040236036&partnerID=8YFLogxK

U2 - 10.1001/jamaoto.2017.1874

DO - 10.1001/jamaoto.2017.1874

M3 - Letter

C2 - 29098291

AN - SCOPUS:85040236036

SN - 2168-6181

VL - 144

SP - 86

EP - 89

JO - JAMA Otolaryngology - Head and Neck Surgery

JF - JAMA Otolaryngology - Head and Neck Surgery

IS - 1

ER -

Association of treatment at high-volume facilities with survival in patients receiving chemoradiotherapy for nasopharyngeal cancer

Access to Document

Other files and links

Cite this